ABSTRACT
Translational medicine is advancing rapidly. Cancer appears to be at the vortex of much of this activity, with proteomic technology emerging and commingling with ongoing genomic analysis for direct bedside applications. Often proteomics is viewed as a list-generating exercise. This view would be wrong, however. The ultimate goal of proteomics, and particularly clinical proteomics, is really threefold:
1. To characterize the information flow through molecular networks in diseased cells and in tissue and how that information content changes during therapeutic intervention.
